Glomerular deposition disease

WikiDoc Resources for Glomerular deposition disease
Articles
Most recent articles on Glomerular deposition disease Most cited articles on Glomerular deposition disease Review articles on Glomerular deposition disease Articles on Glomerular deposition disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Glomerular deposition disease Images of Glomerular deposition disease Photos of Glomerular deposition disease Podcasts & MP3s on Glomerular deposition disease Videos on Glomerular deposition disease
Evidence Based Medicine
Cochrane Collaboration on Glomerular deposition disease Bandolier on Glomerular deposition disease TRIP on Glomerular deposition disease
Clinical Trials
Ongoing Trials on Glomerular deposition disease at Clinical Trials.gov Trial results on Glomerular deposition disease Clinical Trials on Glomerular deposition disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Glomerular deposition disease NICE Guidance on Glomerular deposition disease NHS PRODIGY Guidance FDA on Glomerular deposition disease CDC on Glomerular deposition disease
Books
Books on Glomerular deposition disease
News
Glomerular deposition disease in the news Be alerted to news on Glomerular deposition disease News trends on Glomerular deposition disease
Commentary
Blogs on Glomerular deposition disease
Definitions
Definitions of Glomerular deposition disease
Patient Resources / Community
Patient resources on Glomerular deposition disease Discussion groups on Glomerular deposition disease Patient Handouts on Glomerular deposition disease Directions to Hospitals Treating Glomerular deposition disease Risk calculators and risk factors for Glomerular deposition disease
Healthcare Provider Resources
Symptoms of Glomerular deposition disease Causes & Risk Factors for Glomerular deposition disease Diagnostic studies for Glomerular deposition disease Treatment of Glomerular deposition disease
Continuing Medical Education (CME)
CME Programs on Glomerular deposition disease
International
Glomerular deposition disease en Espanol Glomerular deposition disease en Francais
Business
Glomerular deposition disease in the Marketplace Patents on Glomerular deposition disease
Experimental / Informatics
List of terms related to Glomerular deposition disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Synonyms and keywords: light chain deposition disease

Overview

Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition of fragments of infection-fighting immunoglobulins, called light chains, in the body. These light chain deposits damage organs and cause disease. The kidneys are almost always affected and this often leads to Chronic renal failure. About half of people with light chain deposition disease also have multiple myeloma. Unlike in AL Amyloidosis, in which light chains are laid down in characteristic amyloid deposits, in LCDD, light chains are deposited in non-amyloid granules. Light chains in LCDD are kappa light chains in granular shape.

Classification

There is no established system for the classification of LCDD.

Pathophysiology

Pathogenesis:

The exact pathogenesis of light chain deposition disease is not fully understood. Accumulation of monoclonal light chains and matrix proteins → ↑ quantity and activity of transforming growth factor-beta (TGF-beta).

• TGF-beta → inhibit mesangial cell proliferation and ↑ matrix protein production
• ↑ matrix proteins accumulation → compress the glomerular capillaryies → renal failure .

Genetics

There exact genetic association for LCDD is unknown.

Causes

The specific etiology is unknown.

Differentiating from Other Diseases

• Amyloidosis
• Diabetic Nephropathy
• IgA Nephropathy
• Multiple Myeloma
• Cryoglobulinemia

Epidemiology and Demographics

The incidence of LCDD is unknown. Most of the patients are men with the mean age of 58 years .

Renal involvement is the most common cause of mortality and morbidity in these patients.

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

Prognostic factors at presentation :

• Age
• underlying hematologic disease
• Light chain deposition in other organs
• Renal function
• other medical diseases like diabetic nephropathy

The median time to progression to chronic renal failure is 2.7 years. After 5 years, about 37% of patients with LCDD are alive and do not have end stage renal disease.

Diagnosis

Diagnostic Study of Choice

• Complete blood test
• Urine and serum electrophoresis
• serum assays for immunoglobulin free light chains

History and Symptoms

All organs can be effected by LCDD. Most of the time kidney is involved . Usually patients are asymptomatic in early stages. Rapidly progressive glomerulonephritis or acute tubulointerstitial nephritis cause renal failure in these patients. Other than the kidneys, liver and heart are the most commonly involved organs. Deposition of light chains in the liver may lead to hepatomegaly, an enlarged liver, or rarely portal hypertension or liver failure. The heart is affected in up to 80% of patients with LCDD, and may cause arrhythmias restrictive cardiomyopathy, cardiomegaly, and congestive heart failure .

Physical Examination

• Depends on involvement of the organ you may find organomegaly like hepatomegaly
• Polyneuropathy

Laboratory Findings

• Proteinuria (30-50% of cases have nephrotic syndrome)
• Hematuria (usually microscopic)

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

There is no standard treatment for LCDD. High-dose melphalan in conjunction with autologous stem cell transplantation has been used in some patients. A regimen of bortezomib and dexamethasone has also been considered.

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

Template:WikiDoc Sources